| 臺大學術典藏 |
2021-03-14T23:24:21Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang, Fan Chi; Chen, Tom Wei Wu; Huang, Thomas Tao Min; WEI-CHOU LIN; Liu, Jia Sin; WEN-CHIH CHIANG; YUNG-MING CHEN; Chiun Hsu; KUN-HUEI YEH; TZONG-SHINN CHU |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Chiun Hsu;Cheng A.-L.; Lu L.-C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.;Liu T.-H.;Chiun Hsu;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.; Shao Y.-Y.; Liu T.-H.; Chiun Hsu; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.;Chiun Hsu;Jeng Y.-M.;Hu F.-C.;Pan H.-W.;Wu Y.-M.;Hsu H.-C.;Cheng A.-L.; Lin Z.-Z.; Chiun Hsu; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:47Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chiun Hsu;Yoshino T.;Douillard J.-Y.; Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Shen Y.-C.; Tabernero J.; Yen Y.; Chiun Hsu; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.;Wang S.-Y.;Lin S.-M.;Chen K.-Y.;Tseng J.-H.;Ho M.-C.;Lee R.-C.;Liang P.-C.;Liao L.-Y.;Huang K.-W.;Hu J.-T.;Liang J.-D.;Kee K.-M.;Lin C.-L.;Wang C.-K.;Lu S.-N.;Wang J.-H.;Lee W.-C.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Wang C.-C.;Wang T.-E.;Chuang P.-H.;Dai C.-Y.;Chiun Hsu;Chen S.-C.;Hsieh C.-H.;Diagnosis Group, Systemic Therapy Group; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Chiun Hsu; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Corrigendum to Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Dela Cruz C.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.;Shao Y.-Y.;Chiun Hsu;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; Shao Y.-Y.; Chiun Hsu; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.;Tsai K.K.;Hsiao C.-F.;Yang S.-H.;Hsiao H.-H.;Shen W.-C.;Chiun Hsu;Lin Y.-L.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; Yang S.-H.; Hsiao H.-H.; Shen W.-C.; Chiun Hsu; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.;Kang Y.-K.;Kim T.-Y.;El-Khoueiry A.B.;Santoro A.;Sangro B.;Melero I.;Kudo M.;Hou M.-M.;Matilla A.;Tovoli F.;Knox J.J.;Ruth He A.;El-Rayes B.F.;Acosta-Rivera M.;Lim H.-Y.;Neely J.;Shen Y.;Wisniewski T.;Anderson J.;Chiun Hsu; Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; Chiun Hsu |
